PUBLICATION

Zebrafish models in neuropsychopharmacology and CNS drug discovery

Authors
Khan, K.M., Collier, A.D., Meshalkina, D.A., Kysil, E.V., Khatsko, S.L., Kolesnikova, T., Morzherin, Y.Y., Warnick, J.E., Kalueff, A.V., Echevarria, D.J.
ID
ZDB-PUB-170222-11
Date
2017
Source
British journal of pharmacology   174(13): 1925-1944 (Review)
Registered Authors
Kalueff, Allan V.
Keywords
Behavioral models, Genetic Models, Model organism, Preclinical study, Toxicology models, Zebrafish
MeSH Terms
  • Animals
  • Central Nervous System Agents/chemical synthesis
  • Central Nervous System Agents/chemistry
  • Central Nervous System Agents/therapeutic use*
  • Central Nervous System Diseases/drug therapy*
  • Disease Models, Animal*
  • Drug Discovery*
  • Drug Evaluation, Preclinical
  • Small Molecule Libraries/chemical synthesis
  • Small Molecule Libraries/chemistry
  • Small Molecule Libraries/therapeutic use*
  • Zebrafish
PubMed
28217866 Full text @ Br. J. Pharmacol.
Abstract
Despite high prevalence of neuropsychiatric disorders, their etiology and molecular mechanisms remain poorly understood. The zebrafish (Danio rerio) is increasingly utilized as a powerful animal model in neuropharmacology research and in-vivo drug screening. Collectively, this makes zebrafish a useful tool for drug discovery and the identification of disordered molecular pathways. Here, we discuss zebrafish models of selected human neuropsychiatric disorders and drug-induced phenotypes. Covering a broad range of brain disorders (from anxiety and psychoses to neurodegeneration), we also summarize recent developments in zebrafish genetics and small molecule screening, which markedly enhance the disease modeling and the discovery of novel drug targets.
Genes / Markers
Figures
Expression
Phenotype
Mutations / Transgenics
Human Disease / Model
Sequence Targeting Reagents
Fish
Antibodies
Orthology
Engineered Foreign Genes
Mapping